ProMIS Neurosciences: Top-line Data From First-In-Human Phase 1A Trial of PMN310 to Treat Alzheimer's Disease on Track for Mid-2024 >PMN
ProMIS Neurosciences: Top-line Data From First-In-Human Phase 1A Trial of PMN310 to Treat Alzheimer's Disease on Track for Mid-2024 >PMN
ProMis Neurosciences：用於治療阿爾茨海默氏病的首次人體 1A 期試驗的主要數據有望在 2024 年中期進行 >PMN PMN310
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊